This web site is part of the Business Intelligence Division of Informa PLC
Drug Names(s): azacitidine, AZA-001, AZA001, NS-17
Description: In addition to its cytotoxic effects, Vidaza is a member of a class of drugs in development known as hypomethylating or demethylating agents. Methylation of DNA is a major mechanism regulating gene expression. Researchers have determined that an increase in methylation of DNA can result in blockage of the activity of genes that regulate cell division and differentiation, known as suppressor genes. With suppressor gene expression blocked, cell division becomes unregulated, causing or promoting cancer. In studies, researchers have demonstrated that azacitidine can reverse the methylation of DNA, leading to reexpression of suppressor genes and a resulting differentiation and maturation of cells.
Deal Structure: Pharmion licensed worldwide exclusive rights to Vidaza from Pharmacia & Upjohn Company, now a part of Pfizer, in June 2001. Under the terms of our agreement, the company is obligated to pay Pfizer a royalty of 8% to 20% on net sales of Vidaza. The license from Pfizer has a term extending for the longer of the last to expire of valid patent claims in any given country or ten years from our first commercial sale of the product in a particular country.
Pharmion Corporation and Nippon Shinyaku announced in November 2006 the completion of an exclusive license agreement for development and commercialization rights to Vidaza in Japan. Terms of the agreement were not disclosed.
The agreement requires Nippon Shinyaku to pay both royalties and milestone payments to Pharmion upon the achievement of certain regulatory and sales milestones, and also provides Nippon Shinyaku the responsibility for funding and conducting additional studies required for approval in Japan.
In November 2007,...See full deal structure in Biomedtracker
Partners: Nippon Shinyaku Co., Ltd. Novartis AG
Additional information available to subscribers only: